PreFIT study aims to evaluate the accuracy, feasibility and cost-effectiveness of new and existing point-of-care Tuberculosis diagnostic tests.

Predicting the Future: Incipient Tuberculosis (PreFIT) aims to find better diagnostic tests that allow identifying people with a high risk of developing tuberculosis (TB) disease in an early stage so that they can receive preventive treatment. PreFIT is a multicenter study of new and existing point-of-care diagnostic tests to evaluate their accuracy, feasibility and cost-effectiveness for predicting that tuberculosis-exposed individuals will develop TB disease over a period of 12 months.

The study is funded by the EU (EDCTP), and will enroll 4,000 household contacts of infectious TB patients in Mozambique, South Africa and Uganda. Data collection will start early 2021, the study will be completed by early 2024. The results will inform global introduction of new TB prediction tests to enable scale-up of preventive TB treatment, with the ultimate goal of reducing TB morbidity, mortality and transmission.  

Contact: Frank Cobelens:

Researchers involved